Skip to content
Screener

NeoGenomics NEO Reportable Segment — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
YSS
YSSReportable Segment — R&D
$5.29M+20.2%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2.13B+183%
Enterprise value$2.43B+264%
P/S2.8×+1.7×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Stock-based compensation8,21612,21517,85222,969
Other cost of revenue(1)101,83195,525199,715181,342
Other general and administrative(1)48,56952,83697,614103,585
Other research and development(1)9,9347,85918,39316,961
Other sales and marketing(1)26,66623,21750,14244,927
Impairment charges20,04120,041
Loss from operations(9,771)(47,628)(28,012)(75,453)
Interest income1,2142,2632,4875,984

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — R&D?
NeoGenomics (NEO) reported reportable segment — R&D of $9.93M in Q2 2026.
How has NeoGenomics's reportable segment — R&D changed year-over-year?
NeoGenomics's reportable segment — R&D increased by 26.4% year-over-year, from $7.86M to $9.93M.
What is the long-term trend for NeoGenomics's reportable segment — R&D?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — R&D has grown at a 4.5% compound annual growth rate (CAGR), from $28.49M to $32.54M.
What does reportable segment — R&D mean?
Expenditures dedicated to the discovery and development of new diagnostic tests, technologies, or service enhancements within the segment. This reflects the company's commitment to long-term innovation and maintaining a competitive edge in genetic testing.

Ask your AI about NeoGenomics's reportable segment — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude